Category Archives: Tech Stocks

Hot High Tech Stocks To Own For 2019

Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive,” and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.

That being said, low-priced stocks can be attractive to smaller investors that can’t necessarily afford large stakes in companies with higher priced shares. When looking at these low-priced stocks, we can look at the same trends in growth, value, and momentum and apply the Zacks Rank to properly analyze the potential that these companies have.

Today we’ve highlighted five stocks that are currently trading for under $10 per share. All of these stocks currently sport a Zacks Rank #2 (Buy) or better, and the selected companies are showing signs of outpacing the market in the current calendar year.

Check out these five great stocks under $10 for 2018:

Hot High Tech Stocks To Own For 2019: Commercial Vehicle Group, Inc.(CVGI)

Commercial Vehicle Group supplies interior systems, vision safety solutions and other cab-related products for the global commercial vehicle market. CVGI is holding a Zacks Rank #2 (Buy) and looks undervalued at its current share price levels. The stock is trading with a P/E of just 5.7, which is a significant discount compared to its industry and the broader market. CVGI also has a P/S of 0.3 and a P/CF of 7.6%—both of which support a value argument. And of course, it is worth noting that CVGI’s earnings are expected to grow by 200% in 2018, so this undervaluation is not necessarily coming during a period of business weakness.

Hot High Tech Stocks To Own For 2019: IEC Electronics Corp.(IEC)

IEC Electronics is a provider of electronic contract manufacturing services, including circuit cards, cable loads, and wire harness assemblies. The stock obviously sticks out because of its Zacks Rank #1 (Strong Buy), but investors might also believe it is undervalued at current share prices for a number of other reasons.

Notably, IEC is trading at just 13x forward earnings, which is sharp discount from its industry’s average of 19.6x. Meanwhile, IEC has a P/S ratio of 0.6, which is also a discount to its industry peers. We should also note that IEC is expected to witness quadruple-digit EPS growth in 2018, and its earnings estimates have trended significantly higher over the past quarter.

Hot High Tech Stocks To Own For 2019: Vuzix Corporation(VUZI)

Vuzix is a supplier of smart-glasses and augmented reality (AR) technologies and products for the consumer and enterprise markets. Its wearable displays are used for 3D gaming, manufacturing training, and military tactical equipment. VUZI is a obviously a member of a trendy growth industry, but the stock is also interesting right now due to its Zacks Rank #2 (Buy).

Vuzix is still in the red, but the company is inching toward profitability and is expected to improve EPS figures by 31% this year and 29% next year. Meanwhile, revenue growth is expected to touch nearly 200% in 2018 and 93% in 2019.

New products and mainstream adaption should continue to fuel these estimates. VUZI still feels like a speculative growth stock that could be volatile, but an improving outlook is signaling that now is a solid time to buy.

Top Stocks To Invest In 2019

Money Morning Quantitative Specialist Chris Johnson has two top picks for the best healthcare stocks to buy in July.

Chris’ proprietary "Best in Breed" (BiB) system finds both aggressive companies and discovers undervalued sectors poised for massive gains.

The Gains on This One $10 Stock Alone Could Earn You Enough to Retire – Click Here Now for Details

And his BiB system has uncovered breakout potential for the healthcare industry.

That led Chris to take a deep dive into the sector, and he came away with two healthcare stocks with huge upside potential…

Top Stocks To Invest In 2019: Celgene Corporation(CELG)

I’ve owned Celgene when its stock was hot, and I’ve owned it when it was not. There hasn’t been much heat for the big biotech over the last year. However, my hunch is that will change.

Celgene stock trades at less than eight times expected earnings. The biotech stock is cheap for two primary reasons. First, Celgene depends on Revlimid for 63% of its total revenue, and generic-drug makers are challenging the patents for Revlimid. Second, the company has experienced some pipeline setbacks, which makes investors even more anxious about the potential threat to Revlimid. These factors arguably make Celgene the riskiest big biotech stock on the market.

But Celgene continues to deliver exceptionally strong earnings. I don’t see the stock going much lower as long as that doesn’t change — and I don’t think it will. Any good news should provide a nice catalyst for the biotech. What’s more, the mere anticipation of good news should boost the stock.

Investors have plenty of anticipating to do. Celgene should file yet again for approval of ozanimod in treating multiple sclerosis in early 2019. Solid phase 3 results for luspatercept in treating myelodysplastic syndromes (MDS), a group of rare blood disorders, should lead to regulatory filings in the first half of next year. Celgene also expects to submit cell therapy liso-cel (formerly known as JCAR017) for approval in 2019.

Those are just three potential blockbusters that Celgene has percolating in its pipeline, and there are more. In my view, the growth prospects for the biotech are really good. They’re so good that I don’t think Celgene will remain such a bargain for much longer.

Top Stocks To Invest In 2019: Royal Dutch Shell plc(RDS-A)

Royal Dutch Shell put up an almost unbelievable $14.2 billion in free cash flow in the last 12 months. That allows it to simultaneously reward shareholders with a 5.5% dividend yield and and position itself as a prime player in the future of energy — more specifically, in the coming transition from gas to electric transportation. 

The world’s largest oil companies are getting hip to that game by making giant, multibillion-dollar investments in electric utilities and renewable energy technologies. Holland’s prized oil producer isn’t risking getting left behind, planning to spend up to $2 billion per year on non-fossil energy sources. So far, so good. 

Royal Dutch Shell owns a 44% stake in solar project manager Silicon Ranch, it acquired U.K. electricity provider First Utility, and it owns natural gas distributor and solar technology developer MP2 Energy. That provides a solid foundation upon which to build, but it’s important for investors to note that management sets a high bar for its renewable investments.

All of its acquisitions in electricity distribution and electricity generation are expected to deliver equity rates of return of 8% to 12%, in addition to free cash generation within the next five years. In other words, Royal Dutch Shell (and a few other oil majors) isn’t just gobbling up renewable energy assets to collect shiny objects for an expensive PR game; it’s thinking strategically when deploying capital. That long-term thinking, when coupled with its impressive dividend yield, makes this oil stock a buy for investors committed to the long haul. 

Top Stocks To Invest In 2019: Eli Lilly and Company(LLY)

On Feb. 9, LLY dropped to a three-year low. Since then, it’s risen 16%. That climb moved the stock to trading higher than its 50-day and 200-day moving averages.

That sort of momentum – pushing it above its moving averages – is a sign the stock is heading even higher.

best healthcare stocks to buymoneymorning.com/wp-content/blogs.dir/1/files/2018/07/benjamin_pill-75×50.jpg 75w” sizes=”(max-width: 300px) 100vw, 300px” title=”best healthcare stocks to buy” style=”font-size: 18.0018px; box-sizing: border-box; margin: 0px 0px 24px 24px; padding: 0px; border: 0px; vertical-align: middle; max-width: 100%; height: auto; float: right; text-align: right;” />

In fact, the trend lines just formed a "golden cross," one of the most bullish technical indicators investors can use. In a golden cross, the 50-day moving average rises higher than the 200-day moving average, a classic bullish sign.

The last time that happened was in February 2017 when LLY was in the midst of a killer rally that sent the market up 35% over a five-month stretch.

It gets even better. Short interest grew 20% over the past month, which means a short squeeze could push the stock even higher if the rally continues.

Given that all the signals are indicating more upside, Chris has a price target on LLY of $90 per share. That’s slightly above the highs of October and December. That move might give a double if investors play the $85 call with an Aug. 17, 2018 expiration.

But LLY isn’t the best healthcare stock on our list…